This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Spanish: ICF General field: Medical Detailed field: Medical (general)
Source text - English A placebo is a “dummy drug” and does not contain active medication, i.e., it won’t contain lebrikizumab; therefore, it does not provide a treatment benefit itself. A placebo group is an important part of a clinical study. It is used to try and make sure that any treatment effects that are seen are caused by the study medication and nothing else, since a comparison can be made at the end between patients that received lebrikizumab and those that received placebo.
After 52 weeks, you will enter the active treatment extension. This period may last for up to another 52 weeks. During this period, you will be guaranteed to receive lebrikizumab because no patients will be given placebo. If you were in Groups 1 or 2 during the placebo-controlled period, you will continue to receive the same medication in the active treatment extension period.
Translation - Spanish El placebo es una “medicación de simulación” y no contiene medicamento activo, es decir, no contiene lebrikizumab; por lo tanto, no brinda ningún beneficio de tratamiento en sí mismo. El grupo tratado con placebo constituye una parte importante de un estudio clínico. Se utiliza para intentar y asegurarse de que los efectos del tratamiento observados se deben al medicamento del estudio y nada más, dado que puede hacerse una comparación al final entre los pacientes que recibieron lebrikizumab y los que recibieron placebo.
Después de 52 semanas, ingresará al período de extensión del tratamiento activo. Este período puede durar hasta otras 52 semanas. Durante este período, se le garantiza que recibirá lebrikizumab porque ningún paciente recibirá placebo. Si pertenece a los grupos 1 o 2 durante el período controlado por placebo, continuará recibiendo el mismo medicamento en el período de extensión del tratamiento activo.
More
Less
Translation education
Bachelor's degree - Universidad del Salvador
Experience
Years of experience: 28. Registered at ProZ.com: Jul 2014.
I've got my degrees as a Professional English/Spanish Translator in 1992 both as Scientific Literary Translator and as Sworn Translator which is certified by my local regulatory agency for Translators (Colegio de Traductores Públicos de la Ciudad de Buenos Aires).
I offer translation and proofreading services from English into Spanish. My areas of specialty are Medicine/Pharmacy, Law and Education. In these fields, I've been involved in large projects (+600K) as a translator, proofreader, and a freelance PM coordinating a team of up to 8 professionals (translators, proofreaders, DTP).
I use Trados and WF Pro on a daily basis.
I'm highly commited with every project I take, and I offer flexibility as needed.
Feel free to contact me directly for any questions, or to request my CV. I'll reply to you as soon as possible.
Portfolio 